MaaT Pharma (MAAT) Stock Statistics & Valuation Metrics

MaaT Pharma has a market cap or net worth of €75.39M. The enterprise value is €69.61M.

MaaT Pharma has 16,135,971 shares outstanding. The number of shares has decreased by -2.65% in one year.

MaaT Pharma’s return on equity (ROE) is -2.80 and return on invested capital (ROIC) is -93.63%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, MaaT Pharma had revenue of 3.22M and earned -28.90M in profits. Earnings per share was -2.20.

In the last 12 months, operating cash flow was -22.03M and capital expenditures -707.00K, giving a free cash flow of -22.74M billion.

MaaT Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

MaaT Pharma upcoming earnings date is Sep 16, 2025, Before Open (Confirmed).

MaaT Pharma as a current ratio of 1.90, with Debt / Equity ratio of 154.39%

In the past 12 months, MaaT Pharma has paid -3.52M in taxes.

MaaT Pharma EV to EBITDA ratio is -3.79, with an EV/FCF ratio of -4.38.

MaaT Pharma has €20.22M in cash and marketable securities with €15.96M in debt, giving a net cash position of -€4.26M billion.

Gross margin is 34.45%, with operating margin of -883.96%, and net profit margin of -898.76%.

The average price target for MaaT Pharma is €18.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy